

3rd Dose Vaccine Availability across provinces

Province	Specific Criteria	Link to additional information regarding the 3 rd COVID-19 vaccine dose
Alberta	<p>For Immunocompromised individuals</p> <p>Immunocompromised Albertans 12 and older:</p> <p>Eligible immunocompromising conditions include:</p> <ul style="list-style-type: none"> • recipients of chimeric antigen receptor (CAR)-T-cell therapy • moderate to severe primary immunodeficiency (for example, DiGeorge syndrome, Wiskott-Aldrich syndrome) • Stage 3 or advanced HIV infection and acquired immunodeficiency syndrome • immunosuppressive therapies (for example, anti-B cell therapies, high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents) • transplant recipients, including solid organ and hematopoietic stem cell transplants • chronic kidney disease receiving regular dialysis • receiving active cancer treatment (chemotherapy, immunotherapy or targeted therapies), excluding those receiving only hormonal therapy, radiation therapy or surgery • taking certain medications for autoimmune diseases including rituximab, ocrelizumab and ofatumumab 	<p>https://www.alberta.ca/covid19-vaccine.aspx</p>

British Columbia	<p>At this time, third doses are not available to the general population including for travel or as a booster. For most people, getting two doses of vaccine is highly effective at preventing COVID-19 and boosters are not needed right now.</p> <p>People with moderately to severely compromised immune systems will generally have lower antibody responses from two COVID-19 vaccine doses. Studies show that giving a third dose to complete the initial vaccine series can help these individuals create antibodies to protect them from COVID-19. People who are moderately to severely immunocompromised and meet the criteria will receive a third dose of vaccine.</p> <p>You will be contacted by the provincial Get Vaccinated system about how and when to book a third dose, about 4 weeks after you receive your second dose.</p> <p>If you've selected email or SMS communication, you'll be sent a link to book an appointment online. If you've asked to be contacted by phone, a call centre agent will call you to book an appointment. If you believe you meet the criteria of people who are moderately to severely immunocompromised and haven't been contacted by October 8, get in touch with your health care provider.</p> <p>For moderately to severely immunocompromised dose 3 criteria.</p> <p>Are on active treatment with the following categories of immunosuppressive therapies:</p> <ul style="list-style-type: none">• Since January 2020, been treated with anti-CD20 agents: rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab, tositumomab	<p>https://www2.gov.bc.ca/gov/content/covid-19/vaccine/register</p>
-------------------------	--	--

	<ul style="list-style-type: none">• Since January 2020, been treated with B-cell depleting agents: epratuzumab, MEDI-551, belimumab, BR3-Fc, AMG-623, atacicept, anti-BR3, alemtuzumab• Since December 15, 2020 been treated with biologics: abatacept, adalimumab, anakinra, benralizumab, brodalumab, canakinumab, certolizumab, dupilumab, etanercept, golimumab, guselkumab, infliximab, interferon products (alpha, beta, and pegylated forms), ixekizumab, mepolizumab, natalizumab, omalizumab, reslizumab, risankizumab, sarilumab, secukinumab, tildrakizumab, tocilizumab, ustekinumab, or vedolizumab• Since December 15, 2020 been treated with oral immune-suppressing drugs: azathioprine, baricitinib, cyclophosphamide, cyclosporine, leflunomide, dimethyl fumerate, everolimus, fingolimod, mycophenolate, siponimod, sirolimus, tacrolimus, tofacitinib, upadacitinib, methotrexate, dexamethasone, hydrocortisone, prednisone, methylprednisolone, or teriflunomide• Since December 15, 2020 been treated with steroids orally or by injection on an ongoing basis: dexamethasone, hydrocortisone, methylprednisolone, or prednisone <p>Since December 15, 2020, been treated with immune-suppressing Infusions/injections: cladribine, cyclophosphamide, glatiramer, methotrexate</p>	
--	--	--

Manitoba	<p>Third doses are recommended for the following very specific circumstances in Manitoba at this time, and are not recommended as boosters for the general population:</p> <ul style="list-style-type: none">▪ individuals who have only received a viral vector vaccine (NEW, Oct. 6, 2021);▪ health care personnel who have direct contact with patients, residents or clients (NEW, Oct. 6, 2021);▪ people who are moderately to severely immunocompromised due to a medical condition and/or treatment;▪ individuals who have received one or two doses of a vaccine that is not approved by Health Canada.▪ residents of all personal care homes; and▪ residents and staff of First Nation personal care homes;▪ People who are travelling <p>Immuno-Compromised Eligibility</p> <p>For individuals who meet the specific criteria, a third dose is recommended to complete their COVID-19 vaccination series and offer the best protection. Doctors and scientists have monitored the immune response carefully and recommend a third dose for individuals who:</p> <ul style="list-style-type: none">▪ Have cancer and are are receiving active chemotherapy (or immunotherapy including CAR-T therapy)▪ Have received a solid organ transplant and are receiving chemptherapy or other immunosuppressive therapy▪ Were born with a moderate or severe dysfunction of their immune system▪ Are living with untreated or advanced (stage 3 or advanced) HIV and those with AIDS	<p>https://www.manitobavaccine.ca/third-dose-eligibility/</p>
-----------------	---	--

	<ul style="list-style-type: none"> ▪ Are taking certain medications that severely affect the immune system, including: <ul style="list-style-type: none"> ▪ Anti-B cell therapies ▪ High-dose systemic corticosteroids ▪ Alkylating agents, antimetabolites, or tumornecrosis factor (TNF) blockers ▪ Other biologic agents that are significantly immunosuppressive, including TNF blockers, certain biologic agents (e.g., rituximab), mycophenolate, tacrolimus, Jak inhibitors, methotrexate, fingolimod, azathioprine and leflunomide 	
<p>New Brunswick</p>	<p>Effective September 23rd, third doses will be available to individuals who have the likelihood of having a lower immune response after two doses, related to being moderately to severely immunocompromised due to a medical condition or treatment.</p> <p>People aged 12 and over with at least one of the conditions or treatments listed below are eligible to register online for a third vaccination through a regional health authority clinic or participating pharmacy. These individuals will be asked to sign a statement attesting that they meet the eligibility criteria.</p> <p>The recommended interval for a third dose of mRNA vaccine for immunocompromised people is at least four weeks after their second dose.</p> <p>A complete list of medical conditions and treatments that would result in a person being recommended to receive a third dose is available online.</p>	<p>https://www2.gnb.ca/content/gnb/en/corporate/promo/covid-19/nb-vaccine.html#14</p>

	<p>The list includes people who:</p> <ul style="list-style-type: none"> • Are receiving active chemotherapy (or immune therapy) for cancer. • Have received a solid organ transplant and are currently receiving chemotherapy or other immunosuppressive therapy. • Were born with moderate or severe dysfunction of their immune system. • Are living with untreated or advanced HIV infection or AIDS. • Are taking certain medications that severely affect the immune system. <p>Have chronic conditions associated with varying degrees of immune deficit, such as asplenia and chronic renal disease with dialysis.</p>	
<p>Newfoundland and Labrador</p>	<p>Moderately to severely immunocompromised individuals should be immunized with a third dose of mRNA vaccine (Pfizer-BioNTech or Moderna). Individuals who are moderately to severely immunocompromised may have a lower immune response to COVID-19 vaccines compared to the general population. Individuals with these conditions can have an increased immune response after receiving an additional dose of an mRNA vaccine. Moderately to severely immunocompromised includes people with the following conditions:</p> <ul style="list-style-type: none"> • Active treatment for solid tumour or hematologic malignancies • Receipt of solid-organ transplant and taking immunosuppressive therapy 	<p>https://www.gov.nl.ca/covid-19/vaccine/gettheshot/</p>

	<ul style="list-style-type: none"> • Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy) • Moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome) • Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome • Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (prednisone equivalent of ≥ 2 mg/kg/day or 20 mg/day if weight > 10 kg, for ≥ 14 days), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive. <p>If you meet any of these criteria, you can book a third dose appointment at a Regional Health Authority clinic (select “Second Dose” when booking online), or contact your physician or pharmacist.</p>	
Nova Scotia	<p>Starting 15 October 2021, 1 additional dose of an mRNA COVID-19 vaccine (Pfizer or Moderna) is available to:</p> <ul style="list-style-type: none"> ▪ people who need to travel for work and are unable to travel because the country they need to enter doesn’t recognize a mixed vaccine series ▪ people who are immunocompromised <p>Immunocompromised people, including those taking medications that can substantially affect their immune system, are at higher risk of severe outcomes from COVID-19. The National Advisory Committee on Immunization recommends 1 additional dose of an mRNA COVID-19 vaccine for moderately or severely</p>	<p>https://novascotia.ca/coronavirus/vaccine/#approved-vaccines</p>

	<p>immunocompromised people to increase immune response to the virus.</p> <p>Moderately or severely immunocompromised people who received 2 doses of COVID-19 vaccine can receive 1 additional dose of an mRNA COVID-19 vaccine at least 28 days after their last dose.</p> <p>If you're eligible for an additional dose, you can book an appointment.</p> <p>You also need to bring a list of medications and other supporting documentation (like prescription bottles and insurance notes) to your appointment that shows you meet the criteria for moderate to severe immunocompromise. Vaccination clinics will review your medications and supporting documentation to make sure you're eligible and that your medication substantially affects your immune system.</p> <p>If the vaccination clinic can't confirm you meet the criteria for moderate to severe immunocompromise you can't receive an additional dose of an mRNA COVID-19 vaccine at the clinic.</p> <p>Learn more: moderately or severely immunocompromised and medications that can substantially affect your immune system.</p>	
Nunavut	<p>This recommendation applies to individuals who are 12 years of age and over who have one of the following conditions:</p> <ul style="list-style-type: none"> • Active treatment for solid tumour or hematologic malignancies. • Receipt of solid-organ transplant and taking immunosuppressive therapy. • Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy). 	<p>https://www.gov.nu.ca/munarhiliqiyikkut/news/third-covid-19-vaccine-dose-recommended-immunocompromised-individuals</p>

	<ul style="list-style-type: none"> • Moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome). • Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome. • Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the CIG for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive. 	
<p>Northwest Territories</p>	<p>Immunocompromised: Members of the public are being asked to honestly self-identify if they meet the following criteria determined by the National Advisory Committee on Immunization. You are asked to book vaccination appointments through your local health centre or online in Yellowknife. Individuals will be assessed by a nurse at the time of immunization to confirm eligibility.</p> <p>You may be eligible for a third dose if you meet one of the following criteria:</p> <ul style="list-style-type: none"> • You are undergoing current chemotherapy or radiation therapy for cancer • You have had an organ transplant and you are taking immunosuppressive medications as a result • You have had treatment for leukemia with a stem cell transplant or T-cell therapy in the last two years • You have a specific diagnosis of a severe B-cell or T-cell deficiency • You have advanced untreated HIV, or an active diagnosis of AIDS • You have an autoimmune condition, and you are receiving injectable or intravenous immune suppressing therapy which 	<p>https://www.nthssa.ca/en/newsroom/public-notice-third-dose-vaccinations-specified-frontline-workers-and-immunocompromised</p>

	<p>includes cisplatin, rituximab (Rituxan), gemcitabine, infliximab (Remicade), etanercept (Enbrel), adalimumab (Humira), or others; or injectable or oral methotrexate</p> <ul style="list-style-type: none"> You have a condition for which you are currently being treated with oral or injectable steroid at a dose greater than 20mg per day of prednisone, for over two weeks 	
Ontario	<p>Based on the recommendation of the Chief Medical Officer of Health and in alignment with NACI's recommendation, the province will begin offering third doses of the COVID-19 vaccine to additional vulnerable populations:</p> <ul style="list-style-type: none"> Those undergoing active treatment for solid tumors; Those who are in receipt of chimeric antigen receptor (CAR)-T-cell; Those with moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome); Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome; and Those undergoing active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive. 	<p>https://news.ontario.ca/en/backgrounder/1000805/expanded-eligibility-for-third-doses-of-the-covid-19-vaccine</p> <p>COVID-19 Vaccine Third Dose Recommendations</p>
Prince Edward Island	<p>Residents of long-term care and community care facilities are recommended for a third dose of the COVID-19 vaccine. Individuals with moderately to severely immunocompromised with the following conditions are also recommended for a third dose of the COVID-19 vaccine:</p>	<p>https://www.princeedwardisland.ca/en/information/health-and-wellness/questions-about-third-doses</p>

	<ul style="list-style-type: none"> • Active treatment for solid tumour or hematologic malignancies • Receipt of solid-organ transplant and taking immunosuppressive therapy • Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy) • Moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome) • Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome • Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (e.g. 20 mg/day for ≥ 14 days), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive. 	
Quebec	<p>An additional dose of the messenger RNA COVID-19 vaccine is recommended for:</p> <ul style="list-style-type: none"> ▪ People on dialysis <p>Certain people with a weakened immune system, including those:</p> <ul style="list-style-type: none"> ▪ receiving chemotherapy or radiotherapy ▪ taking medication that affects their immune system ▪ living with HIV who have a CD4 cell count lower than 500 / mm³ or who are not on treatment ▪ Residents of residential and long-term care centres (CHSLD) and intermediate and family-type resources (RI-RTF) ▪ People living in private seniors' residences (RPA) 	<p>https://www.quebec.ca/en/health/health-issues/a-z/2019-coronavirus/progress-of-the-covid-19-vaccination/additional-dose-covid-19-vaccine</p>
Saskatchewan	<p>Starting October 4, phase two of the booster program begins. Eligible residents include:</p>	<p>https://www.saskatchewan.ca/government/health-care-administration-and-provider-resources/treatment-procedures-and-</p>

- Residents 80 years and older, six months following their second dose.
- Other immunocompromised and clinically extremely vulnerable individuals as listed below. These populations can receive the booster a minimum of 28 days after their second dose. Those eligible will receive a letter from the Ministry of Health or their physician with instructions on how to receive the booster. Eligible residents must present the letter before immunization will be administered.

1. Individuals with primary or acquired immunodeficiency states:
 - Including but not limited to poorly controlled HIV/AIDS (i.e a current CD4 count of <200 cells/ μ l for adults or children)
 - primary or acquired cellular and combined immune deficiencies
2. Individuals on immunosuppressive or immunomodulating therapy at the time of vaccination including:
 - those who were receiving or had received in the previous 3 months targeted therapy and/or immune modulating therapy for autoimmune disease
 - those who were receiving or had received in the previous 6 months immunosuppressive chemotherapy or radiotherapy for any indication
3. Individuals with chronic immune-mediated inflammatory disease who were receiving or had received immunosuppressive therapy prior to vaccination (ex. methotrexate, azathioprine)
4. Individuals who had received high-dose steroids (equivalent to >40mg prednisolone per day for more than a week) for any reason in the month before vaccination.

[guidelines/emerging-public-health-issues/2019-novel-coronavirus/covid-19-vaccine/vaccine-delivery-phases#booster-doses](https://www150.ca.gov/health-services/immunization/guidelines/emerging-public-health-issues/2019-novel-coronavirus/covid-19-vaccine/vaccine-delivery-phases#booster-doses)

Yukon	<p>Only a small number of people who are immune compromised are eligible to have a 3rd dose</p> <p>People with the following conditions can book a 3rd dose appointment at least 28 days after a 2nd dose:</p> <ul style="list-style-type: none">• active treatment for solid tumour or hematologic malignancies;• receipt of solid-organ transplant while taking an immunosuppressive therapy;• receipt of chimeric antigen receptor (CAR) T-cell therapy (within 2 years);• receipt of hematopoietic stem cell transplant (within 2 years);• moderate to severe primary immunodeficiency (for example, DiGeorge syndrome, Wiskott-Aldrich syndrome);• stage 3 or advanced untreated HIV infection;• those with acquired immunodeficiency syndrome (AIDS);• active treatment with the following categories of immunosuppressive therapies:<ul style="list-style-type: none">○ anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22);○ high-dose systemic corticosteroids (for example, a prednisone dose of ≥ 2 mg/kg per day or ≥ 20 mg per day for ≥ 14 days);○ alkylating agents;○ antimetabolites;○ tumor-necrosis factor (TNF) inhibitors; and○ other biologic agents that are significantly immunosuppressive. <p>Examples of biological agents that reduce immune response include:</p> <ul style="list-style-type: none">• cancer chemotherapy;• radiation therapy;	<p>https://yukon.ca/en/appointments</p>
--------------	--	--

- | | | |
|--|---|--|
| | <ul style="list-style-type: none">• cytotoxic drugs;• calcineurin inhibitors;• biological response modifiers; and• antibodies that target lymphocytes. | |
|--|---|--|

If you're unsure if you're eligible, please contact your health care provider.